Abstract: AIM To evaluate the effects of recombinant human brain natriuretic peptide( rhBNP) in the treatment of patients with chronic heart failure. METHODS 53 cases of chronic heart failure were randomly divided into the group treated with rhBNP and ordinary heart failure medication (23 cases) and the control group only treated with ordinary heart failure medication (30 cases). Right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP), cardiac index (CI) and plasma norepinephrine, angiotensin II, aldosterone were recorded at different time points before and after medication. RESULTS RhBNP in the reduction of RAP, PCWP, PAP, plasma norepinephrine, angiotensin II, aldosterone and after rhBNP medication in the treatment group and there changes between rhBNP group and control were also significant(P<0.05). Thecardiacindex,serumsodium, putassium no significant impact. No significant adverse effect was found. CONCLUSION rhBNP improved hemodynamic status in patients with chronic heart failure and inhibited over activation of plasma norepinephrine, angiotensin II, aldosterone.